Nucleus Biologics now has the leading xeno-free, recombinant, extracellular matrix
SAN DIEGO, Aug. 6, 2019 /PRNewswire/ -- Nucleus Biologics, a leader in precision cell culture, is pleased to announce the acquisition of Primorigen Biosciences LLC, Inc. The addition of Primorigen’s Vitronectin XF™ and platform recombinant protein production technology will play a huge role in Nucleus’ strategy of offering traceable, reproducible and xeno-free (XF) cell culture ecosystems for the cell and gene therapy space. When growing human cells for cell and gene therapy, XF products provide a physiologically relevant environment that has no animal derived components. Vitronectin XF™ is a recombinant extracellular matrix (ECM) that promotes cell proliferation, maintains pluripotency and supports normal colony morphology, for mesenchymal and induced pluripotent stem cells. Vitronectin XF™ is one of the leading ECMs on the market and is human cell derived, full length, fully glycosylated and completely xeno-free. Vitronectin XF™ is sold around the world direct and through distributors. “We are excited to build on the work of the Primorigen team and support our new customers, distributors and suppliers,” said David Sheehan, Founder, President and CEO of Nucleus Biologics. “This product is a foundation stone for a novel pipeline of products that include cGMP Vitronectin XF™, Vitronectin XF™ Microcarriers and other recombinant proteins to be used in our complete media products. If we truly want to speed science, we will need to provide complete, characterized and disclosed ecosystems.” Chuck Oehler, CEO of Primorigen, stated, “The exceptionally strong fit of the Nucleus and Primorigen product portfolios provide a compelling value proposition for customers seeking more complete solutions for cell biology research and production.” About Nucleus Biologics About Primorigen Biosciences Media Contact: View original content to download multimedia:http://www.prnewswire.com/news-releases/nucleus-biologics-acquires-primorigen-biosciences-gains-proprietary-high-yield-recombinant-protein-platform-300896642.html SOURCE Nucleus Biologics |